WO2019090244A3 - Analyse in vitro de grappe de cellules suppressives dérivées de myéloïdes - Google Patents
Analyse in vitro de grappe de cellules suppressives dérivées de myéloïdes Download PDFInfo
- Publication number
- WO2019090244A3 WO2019090244A3 PCT/US2018/059242 US2018059242W WO2019090244A3 WO 2019090244 A3 WO2019090244 A3 WO 2019090244A3 US 2018059242 W US2018059242 W US 2018059242W WO 2019090244 A3 WO2019090244 A3 WO 2019090244A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- myeloid
- derived suppressor
- vitro
- suppressor cell
- cluster analysis
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne un procédé d'identification de l'état immunosuppresseur d'un individu comprenant la détection de la formation d'une formation de groupe de cellules suppressives dérivées de myéloïdes circulantes (MDSC) dans un échantillon de sang obtenu à partir d'un individu. La formation de groupe MDSC peut être identifiée dans des frottis sanguins frais ou dans des échantillons de sang par cytométrie de flux.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762581438P | 2017-11-03 | 2017-11-03 | |
US62/581,438 | 2017-11-03 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2019090244A2 WO2019090244A2 (fr) | 2019-05-09 |
WO2019090244A3 true WO2019090244A3 (fr) | 2019-06-13 |
Family
ID=66331490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2018/059242 WO2019090244A2 (fr) | 2017-11-03 | 2018-11-05 | Analyse in vitro de grappe de cellules suppressives dérivées de myéloïdes |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2019090244A2 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20220395494A1 (en) * | 2019-11-05 | 2022-12-15 | Health Research, Inc. | Combination therapy for cancer |
WO2022132041A1 (fr) * | 2020-12-15 | 2022-06-23 | Agency For Science, Technology And Research | Procédé destiné à caractériser un neutrophile immunosuppressif |
CN114739890B (zh) * | 2022-04-15 | 2022-12-13 | 广州市第一人民医院(广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院) | 人MDSCs在鉴别CAA和AAA中的应用及鉴别试剂盒 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20160096892A1 (en) * | 2014-07-21 | 2016-04-07 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using a cd33 chimeric antigen receptor |
US20170112929A1 (en) * | 2012-09-07 | 2017-04-27 | Kings College London | Vista modulators for diagnosis and treatment of cancer |
US20170131285A1 (en) * | 2014-06-13 | 2017-05-11 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for diagnosing, monitoring and treating cancer |
-
2018
- 2018-11-05 WO PCT/US2018/059242 patent/WO2019090244A2/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170112929A1 (en) * | 2012-09-07 | 2017-04-27 | Kings College London | Vista modulators for diagnosis and treatment of cancer |
US20170131285A1 (en) * | 2014-06-13 | 2017-05-11 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and compositions for diagnosing, monitoring and treating cancer |
US20160096892A1 (en) * | 2014-07-21 | 2016-04-07 | The Trustees Of The University Of Pennsylvania | Treatment of cancer using a cd33 chimeric antigen receptor |
Non-Patent Citations (7)
Title |
---|
CHEN ET AL.: "Recruitment of CD 11b+Ly6C+ monocytes in non-small cell lung cancer xenografts challenged by anti-VEGF antibody", ONCOL LETT., vol. 14, no. 1, 24 May 2017 (2017-05-24), pages 615 - 622, XP055614931, DOI: 10.3892/ol.2017.6236 * |
DING ET AL.: "Critical Role of the mTOR Pathway in Development and Function of Myeloid- Derived Suppressor Cells in lalL/L Mice", AM J PATHOL., vol. 184, no. 2, February 2014 (2014-02-01), pages 397 - 408, XP055614926, DOI: 10.1016/j.ajpath.2013.10.015 * |
KOTSAKIS ET AL.: "Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples", J IMMUNOL METHODS, vol. 381, no. 1-2, 2012, pages 1 - 22, XP028509497, DOI: 10.1016/j.jim.2012.04.004 * |
SINHA ET AL.: "Tumor-Induced Myeloid-derived Suppressor Cell Function is Independent of IFNgamma and IL -4Ra", EUR J IMMUNOL., vol. 42, no. 8, August 2012 (2012-08-01), pages 2052 - 2059, XP055614918, DOI: 10.1002/eji.201142230 * |
STANOJEVIC ET AL.: "A subpopulation that may correspond to granulocytic myeloid-derived suppressor cells reflects the clinical stage and progression of cutaneous melanoma", INT IMMUNOL., vol. 28, no. 2, 2015, pages 87 - 97, XP055614924, DOI: 10.1093/intimm/dxv053 * |
TUCK ET AL.: "Standard Operating Procedures for Serum and Plasma Collection: Early Detection Research Network Consensus Statement Standard Operating Procedure Integration Working Group", J PROTEOME RES., vol. 8, no. 1, 2009, pages 113 - 117, XP055614928, DOI: 10.1021/pr800545q * |
UMANSK Y ET AL.: "The Role of Myeloid-Derived Suppressor Cells (MDSC) in Cancer Progression", VACCINES ( BASEL, vol. 4, no. 4, 3 November 2016 (2016-11-03), pages E36, XP055614921, DOI: 10.3390/vaccines4040036 * |
Also Published As
Publication number | Publication date |
---|---|
WO2019090244A2 (fr) | 2019-05-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2019090244A3 (fr) | Analyse in vitro de grappe de cellules suppressives dérivées de myéloïdes | |
ES2660429T3 (es) | Métodos, reactivos y kits para detectar enfermedad residual mínima | |
EP4397774A3 (fr) | Procédés de codage à barres de molécules d'acide nucléique à partir de cellules individuelles ou de populations de cellules | |
WO2016127107A3 (fr) | Systèmes et procédés d'analyse biologique | |
WO2020123305A3 (fr) | Génération de sondes de capture pour analyse spatiale | |
WO2016115537A3 (fr) | Systèmes, procédés, et appareil pour l'identification et la récupération in vitro de cellules individuelles | |
EP4307310A3 (fr) | Systèmes et procédés de détection et de différenciation d'infection | |
IN2014CN01787A (fr) | ||
JP2013246140A5 (fr) | ||
WO2014160275A3 (fr) | Biomarqueurs pour la fibrose hépatique | |
WO2014152039A3 (fr) | Systèmes et procédés de traitement de particules sans opérateur | |
WO2015157704A3 (fr) | Procédés et compositions de détection de protéines mal repliées | |
WO2018200995A3 (fr) | Systèmes de polybiodétection et d'imagerie orthogonaux | |
EA201892663A1 (ru) | Аналоги фосфолипидного эфира для идентификации и выделения циркулирующих опухолевых клеток | |
EP3029153A3 (fr) | Biomarqueurs de mésothéliomes et leurs utilisations | |
EP3889603A4 (fr) | Procédé de préparation d'un échantillon de lymphocyte pour analyse par cytométrie de flux | |
MX2013001042A (es) | Biomarcadores de cancer pancreatico y usos de los mismos. | |
WO2020092975A3 (fr) | Procédés de dosage de cellules biologiques dans un dispositif microfluidique | |
KR20160143804A (ko) | 세포의 분화 상태의 평가 방법 | |
TR201905062T4 (tr) | Erken granüle hücrelerin (EGC'ler) tanımlanması ve sayılması. | |
CA3094056A1 (fr) | Separation et detection de micro-organismes | |
WO2019055661A8 (fr) | Biomarqueurs de pré-éclampsie ainsi que systèmes et procédés associés | |
WO2018055209A3 (fr) | Méthode de diagnostic de pancréatite aiguë (ap) par détection d'isoforme alpha de glycoprotéine 2 (gp2a) | |
JP2013517459A5 (fr) | ||
CN104698193A (zh) | 一种鉴定恒河猴血型的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 18872951 Country of ref document: EP Kind code of ref document: A2 |